Resumo

PEREZ-ESPARZA, Rodrigo et al. Ketamine, a New Therapeutic Agent for Depression. Rev. Fac. Med. (Méx.) [online]. 2020, vol.63, n.1, pp.6-13.  Epub 05-Mar-2021. ISSN 2448-4865.  https://doi.org/10.22201/fm.24484865e.2020.63.1.02.

Major depressive disorder affects about one in every 10 people in Mexico and is one of the first 5 causes of disability worldwide. Current treatment options are limited and only act upon some factors associated in its physiopathology. Moreover, the effects on depression are not immediate, which is a great limitation in obtaining a benefit over disability caused by this disorder and impedes a rapid action in the scenario of suicidality. Recently, ketamine (an anesthetic) has shown to have antidepressant properties by acting in the glutamate neurotransmission system (while no other current treatment acts on this level). It offers benefits in depressive symptoms in a matter of hours and has proven to be useful in patients that do not benefit from current therapeutic options. Recently, it has been approved for the treatment of depression. However, there are still many questions about its antidepressant mechanisms of action, safety, side effects, among others.

Palavras-chave : Depression; antidepressants; ketamine.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )